The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of adaptive immunity/inflammatory genes with survival in prostate cancer.
 
Austin Hopper
No Relationships to Disclose
 
Harris Benjamin Krause
Employment - Caris Life Sciences
 
Andrew Elliott
Employment - Caris Life Sciences
 
Alex Patrick Farrell
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Leisa Sutton
No Relationships to Disclose
 
Pablo Tamayo
No Relationships to Disclose
 
Hannah Carter
Stock and Other Ownership Interests - MRI Interventions
 
Ahmed Shabaik
No Relationships to Disclose
 
Andrew Sharabi
Stock and Other Ownership Interests - Toragen
Honoraria - Varian Medical Systems
Consulting or Advisory Role - Primmune Therapeutics; Toragen; Varian Medical Systems
Research Funding - Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Toragen
Travel, Accommodations, Expenses - AstraZeneca
 
Peter Kuhn
Stock and Other Ownership Interests - Cansera; Earli; Epic Sciences; forbie; Sampling Human
Consulting or Advisory Role - Epic Sciences
Research Funding - Abbvie; Amgen; Daiichi Sankyo; Fluidigm; Gilead Sciences; Kite, a Gilead company; Lilly; Novartis
Patents, Royalties, Other Intellectual Property - HDSCA liquid biopsy technology developed in the Kuhn laboratory initially at The Scripps Research Institute and subsequently at the University of Southern California and related patents have been licensed for commercial development to Epic Sciences.; Patent 62/783,921: "System and Method for Determining Human Performance". Systems and methods in human performance to determine whether a cancer patient will need unplanned medical care during cancer therapy.
 
Elisabeth I. Heath
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Caris Life Sciences; Genzyme; Janssen; Johnson & Johnson/Janssen; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Sanofi; Seagen
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Calithera Biosciences (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pharmacyclics (Inst); Plexxikon (Inst); POINT Biopharma (Inst); Roche (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
Other Relationship - Caris Centers of Excellence
 
Emmanuel S. Antonarakis
Honoraria - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Celgene (Inst); ClinicalMind; Clovis Oncology (Inst); Constellation Pharmaceuticals; Curium Pharma; Dendreon (Inst); ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Consulting or Advisory Role - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celgene; Clovis Oncology; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Chadi Nabhan
Employment - Caris Life Sciences
 
Napoleone Ferrara
Stock and Other Ownership Interests - Abbvie; Alcon; Amgen; Gilead Sciences; Novartis; Regeneron; Roche
Consulting or Advisory Role - Amgen
Patents, Royalties, Other Intellectual Property - NVasc; Theia
 
Fotis Asimakopoulos
Patents, Royalties, Other Intellectual Property - Patents, patents pending
 
Ida Deichaite
No Relationships to Disclose